Immune-Mediated Disorders Affecting the Spinal Cord and the Spine

被引:6
|
作者
Perez Giraldo, Gina S. [1 ]
Ortiz Garcia, Jorge G. [1 ,2 ,3 ]
机构
[1] Univ Oklahoma, Dept Neurol, Hlth Sci Ctr, 920 Stanton L Young Blvd,Suite 2547, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Div Crit Care Neurol, Hlth Sci Ctr, 920 Stanton L Young Blvd,Suite 2547, Oklahoma City, OK 73104 USA
[3] Univ Oklahoma, Div Stroke & Cerebrovasc Disorders, Hlth Sci Ctr, 920 Stanton L Young Blvd,Suite 2547, Oklahoma City, OK 73104 USA
关键词
Transverse myelitis; Multiple sclerosis; Neuromyelitis optica spectrum disorder; Myelin oligodendrocyte antibody; Neurosarcoidosis; Paraneoplastic myelitis; MULTIPLE-SCLEROSIS; MYELITIS; DIAGNOSIS; PATIENT; DISEASE;
D O I
10.1007/s11910-020-01088-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of Review To review the most recent advances and provide a description of the most common autoimmune diseases causing myelitis and selective spine disorders. The ultimate goal of this article is to facilitate the prompt recognition of these diseases. Recent Findings The recent discovery of biomarkers such as aquaporin 4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies has changed our understanding of autoimmune diseases affecting the spinal cord as well as their treatment and outcomes. Autoimmune neurology is an increasingly evolving field that encompasses a broad spectrum of autoimmune-inflammatory diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Autoimmune disorders of the spinal cord are a heterogeneous group of myelopathies with a broad differential diagnosis and many of them have been recently identified. Prompt recognition of these myelopathies is important as some of them are treatable, which could improve patient outcomes and prevent disability.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Principles and approaches to the treatment of immune-mediated movement disorders
    Mohammad, Shekeeb S.
    Dale, Russell C.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2018, 22 (02) : 292 - 300
  • [32] Understanding gene expression patterns in immune-mediated disorders
    Dedrick, Russell L.
    JOURNAL OF IMMUNOTOXICOLOGY, 2007, 4 (03) : 201 - 207
  • [33] New treatment options for immune-mediated hematological disorders
    Dierickx, Daan
    De Rycke, Anja
    Vanderschueren, Steven
    Delannoy, Andre
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2008, 19 (08) : 579 - 586
  • [34] The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders
    Dierickx, Daan
    Beke, Emilie
    Devos, Timothy
    Delannoy, Andre
    MEDICAL CLINICS OF NORTH AMERICA, 2012, 96 (03) : 583 - +
  • [35] THE ROLE OF THERAPEUTIC APHERESIS IN THE TREATMENT OF IMMUNE-MEDIATED DISORDERS
    Rafajlovski, A.
    Ostojic, G.
    Todorovic, M.
    Balint, B.
    Jevtic, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 683 - 683
  • [36] Abbreviated dose rituximab for immune-mediated hematological disorders
    Fairweather, Helen
    Tuckfield, Annabel
    Grigg, Andrew
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (07) : 554 - 557
  • [37] Advances in Therapies of Cerebellar Disorders: Immune-Mediated Ataxias
    Hadjivassiliou, Marios
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (06) : 423 - 431
  • [38] Spectrum of Movement disorders in pediatric immune-mediated diseases
    Saan, A.
    Linn, K.
    MinAye, A.
    Hlaing, C.
    Ko, K.
    WintAung, H.
    Lin, N.
    WintAung, Y.
    MOVEMENT DISORDERS, 2019, 34 : S615 - S616
  • [39] Azathioprine - a useful treatment for immune-mediated disorders in the horse?
    Divers, T. J.
    EQUINE VETERINARY EDUCATION, 2010, 22 (10) : 501 - 502
  • [40] Immune-mediated rippling muscles with myasthenia gravis, thymoma, and other immune-mediated disorders: A review of the last 25 years
    Ansevin, Carl
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429